

CADDRA's 19th Annual ADHD Conference is scheduled for Saturday and Sunday, September 30 – October 1, 2023 at Le Centre Sheraton Montreal Hotel, at 1201 René-Lévesque Blvd W, Montreal.

This meeting is planned as an in-person event only.

The deadline for abstract submission is **30 April 2023**. Submissions must be made through the online abstract submission portal at [caddra.societyconference.com](http://caddra.societyconference.com).

## Topics

Sessions at the CADDRA conference should provide objective information or teach skills related to ADHD diagnosis or care. Data should be based on scientific methods accepted in the medical community. Abstracts are invited on topics related to applied research; emerging trends; policy change; promising practices; diversity, equity and inclusion; and replicable programs. See below for categories.

## French-language stream

Abstracts are invited for a **French-language stream** which will be held in parallel with the other sessions. Keynotes and symposia will be presented in English only.

## General instructions

- Abstract submission deadline: **30 April 2023**
- Presentation types include seminars, workshops and symposia or French-language session. Posters can be submitted for ADHD Research Day, see separate Research Day Call for Abstracts.
- Each submission must include a title, three learner-centered objectives, an abstract of 250 words maximum and indicate target audience and topic category.
- Topics can include educational material with a focus on applied research; emerging trends; policy change; promising practices; diversity, equity and inclusion; replicable programs.

## For accepted submissions:

- All presenters, discussants and chairs must complete a full disclosure form.
- A minimum of 25% of the total presentation time must be allotted for discussion.
- Presenters must bring a laptop computer for use with a projector. If a Mac computer is used, the presenter must bring a connection cord for projector use.

Note: All **conference presenters** and co-presenters are provided with complimentary registration to the conference in Montreal and an invitation to the Speaker/Member dinner. Travel costs are the responsibility of the presenter.

## Submission Types for 2023

- **Seminar** (60 minutes, including 15 minutes of questions and answers): Conference sessions provide a structured format to cover a topic of interest to healthcare, medical and research professionals working in the field of ADHD. Sessions may be led by one or two presenters.
- **Symposium** (75 minutes, including 20 minutes minimum of questions and answers): A symposium provides a

structured format to a group of experts wanting to present on a common topic relevant to ADHD. Topics addressed in symposiums will be theme and topic specific and presented at a more comprehensive level with three to four speakers (including the chair) providing their viewpoints and experiences. Symposium topics should engage conference audiences in critical reflection and discussion on key issues and should be evidence-based. The chair should submit an overall abstract outlining the content and format of the session and learning objectives along with a short bio and contact information for symposium participants.

- **Workshop** (60 minutes): A workshop is an opportunity for a small group of delegates (up to 30) to be engaged in intensive discussion and activity on a particular topic. It can feature educational material with a particular focus on emerging trends, promising practices, applied research, intervention strategies and replicable programs. In addition to building new knowledge, workshops can educate delegates on particular skills that can be used in a practical setting. These sessions may be structured in the form of a dialogue or debate, case studies and interactive activities.

### Important Dates

- Abstract submission deadline: April 30, 2023 at 11:59pm (EDT)
- Notice of Acceptance: by June 30, 2023
- Presenter Registration Deadline: August 1, 2023\*
- Submission of slides for committee review: September 13, 2023

\*All accepted **conference presenters** receive complimentary registration for the CADDRA conference and an invitation to the Conference Speaker/Member Dinner.

### Submission Instructions

1. Visit [caddra.societyconference.com](https://caddra.societyconference.com)
  - Existing user – log in with your credentials (option to reset password if necessary)
  - New user – create an account
2. Click on Submission box, select your submission type (seminar, workshop, symposium) and follow the online instructions.
  - The following will be required, abstract description (250 words), three [learner-centered objectives](#)
  - Target audience, level of presentation (beginner, intermediate, advanced), key words
  - Brief bio (150 words) and contact emails for all presenters
  - Select the relevant category that applies from the following: Assessment & Management; Clinical Considerations & Symptoms; Cognitive/Neuropsychological Profiles; Community & School-Based Approaches; Contributing/Causal Factors; Comorbidities; Developmental Perspectives; Equity, Diversity & Inclusion; Gender and Sex Differences; Neuroscience, Genetics & Epigenetics; Pharmacological Treatment & Outcomes; Psychosocial Treatment & Outcomes; Research Developments/Future Directions; Other.
  - Add abstract description (250 words), three [learner-centered objectives](#), target audience, level of presentation (beginner, intermediate, advanced), key words, brief bio (150 words) and contact emails for all presenters.

Note: Revisions may be made through the submission portal until April 30, 2023. Proofread carefully! Abstracts will be published as submitted.

### Disclosure Policy

As a CME provider CADDRA requires that individuals (presenters/speakers, moderators, reviewers, authors, and planners) disclose to CADDRA and the audience any *relevant relationships* that have the potential to affect the content of CME. Accepted presenters will be required to complete disclosure forms.

### Presentation Requirements

- Objective information based on scientific methods generally accepted in the medical community.

- If therapeutic options are discussed, a balanced view of therapeutic options should be presented, including potential benefit and harm. Descriptions of therapeutic options should use generic names (or both generic and trade names).
- Data presented should be up-to-date and drawn from scientifically valid sources, references must be included. Lack of evidence for assertions or recommendations must be acknowledged.
- Barriers to physician/practitioner change should be addressed and interventions proposed.

#### **Abstract Review & Notification**

- After the submission deadline, completed abstracts will be peer reviewed by the Scientific Committee.
- Incomplete abstracts cannot be processed and will *not* be reviewed.
- The submitting presenter must incorporate any reviewer feedback before final approval is provided.
- The submitting presenter will receive notification of acceptance/rejection by June 30.
- Accepted presenters will be asked to submit a conflict-of-interest statement, a CV and a headshot along with three multiple choice questions.
- Accepted presenters will be expected to present in person in Montreal.

#### **Registration & Accommodation**

- Submission or acceptance of an abstract does ***not register*** you. All presenters are required to register by August 1 (conference presenters receive complimentary registration to both conference days.). Registration will open in July.
- Travel and hotel accommodation must be organized and paid for by presenters. Learn more about registration and accommodation at [caddra.societyconference.com](http://caddra.societyconference.com)

#### **Need Help?**

If you are having trouble submitting an abstract, or do not receive a confirmation email within 24 hours, email [info@caddra.ca](mailto:info@caddra.ca) for assistance.